340B Drug Pricing Program
The AHA has issued a Special Bulletin with details on provisions of the Centers for Medicare & Medicaid Services’ outpatient prospective payment system final rule for calendar year 2023, which includes updates to policies for the 340B Drug Pricing Program.
While the AHA is pleased that CMS will provide hospitals and health systems with an improved update to outpatient payments next year compared to the agency’s proposal in July, the increase is still insufficient given the extraordinary cost pressures hospitals face from labor, supplies, equipment,…
The Centers for Medicare & Medicaid Services late today posted a final rule on its website that will increase Medicare hospital outpatient prospective payment system rates by a net 3.8% in calendar year 2023 compared to 2022. This update is based on a market basket percentage increase of 4.1%,…
Medicare Administrative Contractors will pay 340B hospitals Average Sales Price plus 6%, rather than ASP minus 22.5%, for all CY 2022 drug claims with modifier “JG,” CMS confirmed for AHA yesterday.
It’s in everyone’s best interest to keep the 340B program strong, wrote AHA President and CEO Rick Pollack in the Congress Blog at The Hill, published Oct. 10.
“For three decades, the 340B drug pricing program has helped hospitals that serve high numbers of low-income patients offer and expand a range of important programs and services that advance health within their communities,” writes AHA President and CEO Rick Pollack in the Congress Blog at The Hill…
After court ruling for AHA in 340B case, HHS says it will start adjusting payment rates for certain 340B hospitals within approximately two weeks
The Department of Health and Human Services will begin restoring a payment rate of average sales price plus 6% for 340B drug claims in about two weeks, the department told a United States District Court for the District of Columbia.
The United States District Court for the District of Columbia Sept 28 ruled in favor of the AHA, holding that the Department of Health and Human Services must immediately halt the departments’ unlawful cuts to outpatient reimbursement rates for the remainder of 2022 for certain hospitals that…
The AHA appreciates Judge Contreras’ ruling that the Department of Health and Human Services must immediately stop unlawful reimbursement cuts for 2022 for hospitals participating in the 340B drug pricing program. Halting these cuts will help 340B hospitals provide comprehensive health services to…